[New Haven, Connecticut, February 8, 2024] — DeepLook Medical, a Connecticut-based technology firm, focused on visual enhancement technology to advance medical imaging, has successfully raised $1.7 million in funding. Connecticut Innovations, Tidal River, Angel Investor Forum (AIF), OKG Capital, Werth Ventures, and various private investors participated in this round.
DeepLook Medical has developed the first AI technology platform designed specifically for the visualization of suspicious masses in dense breasts. The software overlays directly onto existing imaging screens, providing a seamless and efficient workflow enhancement with one-click measurement, segmentation, and visualization.
With approximately 45% of women having dense breasts and an increased risk of breast cancer, it's concerning that nearly 50% of cancers in dense breasts are missed on initial mammograms.
“This technology addresses a significant unmet need in medical imaging, enabling rapid and accurate lesion segmentation, measurement, and visualization” says Dirk Feyants, Executive Vice President of Diagnostic Imaging at Barco. “Combined with our displays’ excellent image quality, this tool offers a new layer of confidence to breast radiologists. We are proud to lead the way with DeepLook Medical in offering breast radiologists the essential tools they require to enhance their patients' well-being."
DL Precise™, the latest flagship product from DeepLook Medical, utilizes the company's unique shape-recognition software to delineate tumor morphology, a critical aspect for improved diagnosis.This FDA-cleared software has recently entered the commercial market through partnerships with four major channel partners including Barco, Blackford, Tempus, and Radical Imaging.
Compatible with various imaging modalities, including mammography, ultrasound, CT, and MRI, DL Precise™, employs a single-click deterministic algorithm for precise lesion segmentation, streamlining workflow efficiency. DeepLook Medical is leveraging other complementary AI advances to further enhance the impact and reach of its patented technology.
"We are thrilled to announce our latest funding which will help us further develop technologies that are critical in helping detect cancer, particularly in dense breast tissue," said Marissa Fayer, CEO of DeepLook Medical. "Our innovative AI technology is a game-changer in the field, offering a streamlined solution for early detection across multiple imaging modalities."
The funds secured in this seed round will be directed towards key areas, including talent acquisition and the advancement of next-generation products. Simultaneously, the allocation will facilitate the expansion of sales and partnerships, as well as strengthen support for additional clinical research and publications. The resources will also be utilized to extend global IP and regulatory protections and clearances.
About DeepLook Medical:
DeepLook Medical, a Connecticut-based software firm, focuses on visual enhancement technology to advance medical imaging. DL Precise™ is the first in a series of innovative products using the company’s unique shape-recognition software to delineate the details of tumor morphology – a key to better diagnosis and treatment of malignancy across the field of oncology. The company is leveraging other complementary AI advances to further the reach and impact of its patented technology. To learn more, please visit: https://www.deeplookmedical.com/